Lyra Therapeutics, Inc. (LYRA) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-05-15

Lyra Therapeutics, Inc. (LYRA) has filed 1 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-15. InsiderAlpha tracks every LYRA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Lyra Therapeutics, Inc. (LYRA)

SIC classification	Surgical & Medical Instruments & Apparatus (SIC 3841)
SEC CIK	0001327273

90-Day SEC Filing Activity

Form 4 filings (90d)	1
Latest Form 4 filing	2026-05-15

Recent LYRA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-05-14	Smith W Bradford	Insider	D — Derivative transaction	640	$0.00	—	SEC
2026-04-01	Cavalier Jason	Principal Financial Officer	D — Derivative transaction	667	$0.00	—	SEC
2026-04-01	Palasis Maria	Principal Executive Officer	D — Derivative transaction	2.0K	$0.00	—	SEC
2026-01-06	Cavalier Jason	Chief Financial Officer	S — Open-market sale [10b5-1]	769	$3.36	$3K	SEC
2026-01-06	Palasis Maria	President & CEO	S — Open-market sale [10b5-1]	1.7K	$3.36	$6K	SEC
2025-11-13	PERCEPTIVE ADVISORS LLC	Insider	S — Open-market sale	3.2K	$3.90	$13K	SEC
2025-11-13	PERCEPTIVE ADVISORS LLC	Insider	S — Open-market sale	28.6K	$3.90	$112K	SEC
2025-11-13	PERCEPTIVE ADVISORS LLC	Insider	S — Open-market sale	3.2K	$3.90	$13K	SEC
2025-11-13	PERCEPTIVE ADVISORS LLC	Insider	S — Open-market sale	28.6K	$3.90	$112K	SEC
2025-11-12	PERCEPTIVE ADVISORS LLC	Insider	S — Open-market sale	883	$4.06	$4K	SEC
2025-11-12	PERCEPTIVE ADVISORS LLC	Insider	S — Open-market sale	7.9K	$4.06	$32K	SEC
2025-11-12	PERCEPTIVE ADVISORS LLC	Insider	S — Open-market sale	883	$4.06	$4K	SEC
2025-11-12	PERCEPTIVE ADVISORS LLC	Insider	S — Open-market sale	7.9K	$4.06	$32K	SEC
2025-11-11	PERCEPTIVE ADVISORS LLC	Insider	S — Open-market sale	537	$4.31	$2K	SEC
2025-11-11	PERCEPTIVE ADVISORS LLC	Insider	S — Open-market sale	537	$4.31	$2K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Lyra Therapeutics, Inc. (LYRA). Updated in real time as new filings are submitted to the SEC.

Most-Active LYRA Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Smith W Bradford	1	—

Recent LYRA Form 8-K Material Events

2026-04-17 — Item 1.02 · Restructuring · negative [SEC]
Lyra Therapeutics terminated its sublease for approximately 23,704 square feet of office space in Waltham, Massachusetts, effective March 31, 2026. The company agreed to pay a $2.1 million termination fee to exit the lease early, indicating cost-cutting and operational restructur
2026-04-10 — Item 1.02 [SEC]
2026-03-16 — Item 3.01 · Restructuring · negative [SEC]
Lyra Therapeutics withdrew its appeal of a Nasdaq delisting determination issued on February 2, 2026. Trading in the company's common stock will be suspended at market open on March 17, 2026, and Nasdaq will file a Form 25 delisting notification with the SEC.
2026-02-27 — Item 2.04 · Restructuring · negative [SEC]
Lyra Therapeutics received a notice of default from its sublease holder for unpaid rent totaling $484,431.92. The company is in wind-down mode following its January 12, 2026 announcement of ceasing operations and pursuing strategic alternatives. The company explicitly states ther

Recent Insider Filings

2026-05-15 — Smith W Bradford (Insider)
2026-04-03 — Palasis Maria (Principal Executive Officer)
2026-04-03 — Cavalier Jason (Principal Financial Officer)
2026-01-08 — Cavalier Jason (Chief Financial Officer)
2026-01-08 — Palasis Maria (President & CEO)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in LYRA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

LYRA Insider Trading — FAQ

What is the latest insider trade for LYRA?: Lyra Therapeutics, Inc. (LYRA) had 1 insider filings in the last 90 days, with the most recent on 2026-05-15. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying LYRA stock?: 0 insider purchases of LYRA were filed in the last 90 days.
How many insiders are selling LYRA stock?: 0 insider sales of LYRA were filed in the last 90 days.
Where can I see LYRA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every LYRA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live LYRA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.